Estrogen Receptor Positive Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting estrogen receptor positive clinical trials across 6 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include Minneapolis, Minnesota, United States, Chicago, Illinois, United States, Adrian, Michigan, United States. Updated daily from ClinicalTrials.gov.


Estrogen Receptor Positive Trials at a Glance

7 actively recruiting trials for estrogen receptor positive are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Minneapolis, Chicago, and Adrian. Lead sponsors running estrogen receptor positive studies include Dana-Farber Cancer Institute, European Institute of Oncology, and Aarhus University Hospital.

Browse estrogen receptor positive trials by phase

Treatments under study

About Estrogen Receptor Positive Clinical Trials

Looking for clinical trials for Estrogen Receptor Positive? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Estrogen Receptor Positive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Estrogen Receptor Positive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Estrogen Receptor Positive TumorEndometrial Stromal SarcomaUterine Sarcoma+6 more
Dana-Farber Cancer Institute30 enrolled1 locationNCT07467772
Recruiting
Not Applicable

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8HER2/Neu Negative+3 more
SWOG Cancer Research Network739 enrolled723 locationsNCT03723928
Recruiting
Phase 4

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Breast CancerNode-positive Breast CancerHER2-negative Breast Cancer+2 more
Gangnam Severance Hospital418 enrolled2 locationsNCT05333328
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting

Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients

Breast CancerEstrogen Receptor Positive Tumor
European Institute of Oncology150 enrolled1 locationNCT06474988
Recruiting
Phase 2

Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Triple-Negative Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer+4 more
Northwestern University100 enrolled1 locationNCT03213041
Recruiting
Phase 3

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Breast Cancer FemaleEstrogen Receptor Positive Tumor
Aarhus University Hospital3,360 enrolled1 locationNCT04601116